Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Two sides to SIRT1

In the last few years, companies have started pursuing agonism of SIRT1 as a way of boosting the body's metabolism to treat Type II diabetes, while other researchers say they have evidence that activating the target might be useful in treating or preventing cancer.

But another camp is arguing that blocking, not activating, SIRT1 or other sirtuins could be used to treat cancer through the upregulation of tumor suppressor proteins. Pharmion Corp. is exploring that mechanism via last week's expanded deal with

Read the full 817 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers